24-Jul-2026
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
PRNewswire (Thu, 28-May 6:10 PM ET)
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
PRNewswire (Thu, 7-May 4:00 PM ET)
PRNewswire (Fri, 1-May 12:23 AM ET)
Market Chameleon (Fri, 27-Mar 6:30 AM ET)
Market Chameleon (Thu, 26-Mar 3:05 AM ET)
Kodiak Sciences' $160 Million Upsized Offering Marks Strategic Bet on Retina Therapeutics
Market Chameleon (Wed, 17-Dec 6:44 AM ET)
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences trades on the NASDAQ stock market under the symbol KOD.
As of July 24, 2026, KOD stock price climbed to $41.41 with 488,381 million shares trading.
KOD has a beta of 3.04, meaning it tends to be more sensitive to market movements. KOD has a correlation of 0.09 to the broad based SPY ETF.
KOD has a market cap of $2.59 billion. This is considered a Mid Cap stock.
In the last 3 years, KOD traded as high as $47.84 and as low as $1.37.
The top ETF exchange traded funds that KOD belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
KOD has outperformed the market in the last year with a price return of +401.9% while the SPY ETF gained +17.7%. However, in the short term, KOD had mixed performance relative to the market. It has underperformed in the last 3 months, returning -7.6% vs +3.8% return in SPY. But in the last 2 weeks, KOD shares have fared better than the market returning +0.2% compared to SPY -2.1%.
KOD support price is $38.95 and resistance is $43.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KOD shares will trade within this expected range on the day.